Stockscreener 앱 받기
10.01
0.00%
0.00
전일 마감가:
$10.01
열려 있는:
$10.01
하루 거래량:
381.88K
Relative Volume:
18.57
시가총액:
$219.29M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+32.81%
6개월 성능:
+20.48%
1년 성능:
+0.00%
1일 변동 폭
$10.01
$10.02
1주일 범위
$10.00
$10.02
52주 변동 폭
$10.00
$10.02
Translational Development Acquisition Corp Stock (TDAC) Company Profile
명칭
Translational Development Acquisition Corp
전화
-
주소
-
TDAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TDAC
Translational Development Acquisition Corp
|
10.01 | 219.29M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
8.31 | 2.40B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.06 | 691.25M | 0 | 16.92M | -1.35M | 0.29 |
|
GCL
Gcl Global Holdings Ltd
|
3.77 | 475.87M | 0 | 0 | 0 | 0.00 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.55 | 454.97M | 0 | 1.30M | 0 | 0.0301 |
|
AAM
Aa Mission Acquisition Corp
|
10.17 | 447.22M | 0 | 0 | 0 | 0.00 |
Translational Development Acquisition Corp Stock (TDAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-21 | 개시 | Northland Capital | Outperform |
Translational Development Acquisition Corp 주식(TDAC)의 최신 뉴스
Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced - Yahoo Finance
Trident Acquisitions stock hits 52-week high of $10.08 - Investing.com
ImmuPharma (LON:IMM) Stock Price Up 9.3% – Here’s Why - Defense World
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Translational Development (TDACU) Raises $172.5M in Successful Nasdaq IPO, Begins Trading - StockTitan
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
(PDF) Measuring Translation Competence Acquisition - ResearchGate
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering & Biotechnology News
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering & Biotechnology News
FirstEnergy issues earnings report - 69News WFMZ-TV
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation - Nature.com
A Stone Capital-backed SPAC braves the blank check waters, looking to grab a $150M deal - Endpoints News
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases - Business Wire
Oak Hill Bio Appoints Tauhid Ali as First Chief Executive Officer - Business Wire
Quotient integrates drug substance into platform - Speciality Chemicals Magazine
Third Rock Ventures Announces Promotion of David Kaufman, M.D., Ph.D., to Partner - Business Wire
Research and Development grant cheat sheet - University of Sydney
A red blood cell disease meets a company with a plasma protein heritage - Nature.com
BioSpace Movers & Shakers, March 19 - BioSpace
BioSpace Movers & Shakers: MoMa Therapeutics, Cerevance, Glympse Bio and More - BioSpace
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio - Business Wire
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development - The Lancet
Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert - GeekWire
Quotient Clinical’s second U.S. acquisition in a row: Charles River’s QS Pharma - Fierce Biotech
People - Nature.com
Translational Development Acquisition Corp (TDAC) 재무 분석
Translational Development Acquisition Corp (TDAC)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.00%
0.10%
자본화:
|
볼륨(24시간):